TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02692144

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Test Cluster
Description: Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Cluster
Description: Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Test Cluster
Description: Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber
Study: NCT03935191

Intervention type: DEVICE
Intervention: Dexcom CGM System
Description: Dexcom CGM System
Study: NCT05001074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release tacrolimus
Description: de novo cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus direct post-lung transplantation Conversion cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus when \>1 year post-lungtransplantation and with stable graft function

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release tacrolimus
Description: de novo cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus direct post-lung transplantation Conversion cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus when \>1 year post-lungtransplantation and with stable graft function

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate release tacrolimus
Description: de novo cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus direct post-lung transplantation Conversion cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus when \>1 year post-lungtransplantation and with stable graft function

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate release tacrolimus
Description: de novo cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus direct post-lung transplantation Conversion cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus when \>1 year post-lungtransplantation and with stable graft function
Study: NCT02867033

Intervention type: PROCEDURE
Group type: OTHER
Intervention: biopsy
Description: pre-therapeutic or post-therapeutic biopsy or resected tissues

Intervention type: OTHER
Group type: OTHER
Intervention: biobank constitution
Description: Constitution of a biobank with pre-therapeutic or post-therapeutic biopsy or resected tissues

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coloscopy
Description: For adult patients, a coloscopy with chromoscopy of ascending and sigmoid colon will be performed

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling (facultative)
Description: Blood sample can be collected at diagnostic or after medically significant events (progressive disease, local or systemic treatment, pregnancy...)

Intervention type: OTHER
Group type: OTHER
Intervention: Pain evaluation
Description: Pain evaluation (EVA scale), anxiety (HADS questionnaire), quality of life questionnaire (EORTC-QLQ-C30)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tumor biobank realization
Description: Realization of a tumor biobank is part of classical procedure of participating centers
Study: NCT03684954

Intervention type: OTHER
Group type: OTHER
Intervention: Prf
Description: Take 10 cc blood from patient and gain prf
Study: NCT04108520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise with respiratory training
Study: NCT00737620

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthetic AV graft implantation
Description: Surgical arteriovenous fistula creation with standard or propaten graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthetic AV graft implantation
Description: Surgical arteriovenous fistula creation with standard or propaten graft
Study: NCT02760667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatinum
Description: Cisplatin 75mg/m2 every 3 weeks for a maximum of 3 cycles during the induction phase
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Clopidogrel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Clopidogrel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Clopidogrel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Clopidogrel

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Clopidogrel

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Clopidogrel
Study: NCT02760667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 every 3 weeks for a maximum of 3 cycles during the induction phase
Study: NCT05454059

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: Routine non-surgical periodontal treatment will be applied to patients with periodontitis. The main aim of non-surgical periodontal treatment is to protect, heal and maintain the existing dentition. For this purpose, using manual, sonic or ultrasonic instruments, microbial dental plaque and calculus are removed by tooth surface cleaning and root surface straightening.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: Routine non-surgical periodontal treatment will be applied to patients with periodontitis. The main aim of non-surgical periodontal treatment is to protect, heal and maintain the existing dentition. For this purpose, using manual, sonic or ultrasonic instruments, microbial dental plaque and calculus are removed by tooth surface cleaning and root surface straightening.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ELISA Test
Description: C1P and PGE2 levels in saliva samples obtained, and will be examined by ELISA test.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISA Test
Description: C1P and PGE2 levels in saliva samples obtained, and will be examined by ELISA test.
Study: NCT02760667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC=5 every 3 weeks for a maximum of 3 cycles during the induction phase (if subject are unable to tolerate cisplatin)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral Robotic Assisted Surgery
Description: TORS will be performed for the patients who responded to the induction treatment (80% reduction)
Study: NCT01230268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulberry fruit extract
Description: 1000 mg oral daily dose for 2 weeks
Study: NCT03761147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paula exercises
Description: structured exercises aimed to stimulate ring muscles
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Clopidogrel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Clopidogrel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Clopidogrel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Clopidogrel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Ramipril

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Ramipril
Study: NCT03104595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: oral administration
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Ramipril

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Ramipril
Study: NCT05454059

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ELISA Test
Description: C1P and PGE2 levels in saliva samples obtained, and will be examined by ELISA test.
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Ramipril

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Ramipril

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Ramipril

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Ramipril

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Ramipril

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Ramipril

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Ramipril

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Ramipril

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Ramipril

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Ramipril

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Ramipril

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Ramipril

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Ramipril

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Ramipril
Study: NCT05454059

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISA Test
Description: C1P and PGE2 levels in saliva samples obtained, and will be examined by ELISA test.
Study: NCT03104595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: oral administration
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Ramipril

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Ramipril

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Ramipril

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Ramipril
Study: NCT03251079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring system
Description: Implanted continuous glucose monitoring system
Study: NCT00423150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide capsules 150 mg/m\^2 daily on a 7-day on / 7-day off schedule for each 28-day cycle, until disease progression, intolerable toxicity, or withdrawal of consent.
Study: NCT05264155

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: GameBus (mHealth app)
Description: Using the mHealth app GameBus, participants could track their performance on 2 social leaderboards: a leaderboard displaying the individual scores of participants and a leaderboard displaying the average scores per department. To score points on these leaderboards, a participant was given a set of 6 tasks that, upon completion, were rewarded with points. In this study, 3/6 tasks were either updated generically (for the control group) or personalized (for the treatment group). By means of the mobile app, users could manually register that they had performed a task. Alternatively, users could use an activity tracker to automatically track their efforts. The activity trackers that were supported included Google Fit, Strava, and a GPS-based activity tracker. Finally, GameBus provided a set of features for social support: a newsfeed showed when other participants had scored points, and participants could like and comment on each other's healthy achievements as well as chat with each other.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GameBus (mHealth app)
Description: Using the mHealth app GameBus, participants could track their performance on 2 social leaderboards: a leaderboard displaying the individual scores of participants and a leaderboard displaying the average scores per department. To score points on these leaderboards, a participant was given a set of 6 tasks that, upon completion, were rewarded with points. In this study, 3/6 tasks were either updated generically (for the control group) or personalized (for the treatment group). By means of the mobile app, users could manually register that they had performed a task. Alternatively, users could use an activity tracker to automatically track their efforts. The activity trackers that were supported included Google Fit, Strava, and a GPS-based activity tracker. Finally, GameBus provided a set of features for social support: a newsfeed showed when other participants had scored points, and participants could like and comment on each other's healthy achievements as well as chat with each other.
Study: NCT04018950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-ETX2514
Description: intravenous infusion
Study: NCT03300479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevidipine
Description: Intravenous antihypertensive therapy with Clevidipine for the first 24 hours in patients with nontraumatic intracerebral hemorrhage (ICH).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urapidil
Description: We compare the therapy with Urapidil to Clevidipine for the acute phase (24 hours) in patients with ICH. We would like to show the efficacy and safety of Clevidipine in this special situation.
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Ramipril

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam
Study: NCT04386616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSTT1041A
Description: Participants received one intravenous (IV) infusion of MSTT1041A 700 milligrams (mg) on Day 1. A second IV dose of MSTT1041A 350 mg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
Study: NCT00529542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipitor
Description: 40mg caplets per day for six weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo caplet per day for six weeks.
Study: NCT02838680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HLT Transcatheter Aortic Valve System
Description: Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
Study: NCT00502177

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: QOL Questionnaires taking a total of 10 minutes to complete.
Study: NCT05454059

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: ELISA Test
Description: C1P and PGE2 levels in saliva samples obtained, and will be examined by ELISA test.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISA Test
Description: C1P and PGE2 levels in saliva samples obtained, and will be examined by ELISA test.
Study: NCT04386616

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MSTT1041A-matched Placebo
Description: Participants received up to 2 intravenous infusions of MSTT1041A-matched placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTTR1147A
Description: Participants received one intravenous (IV) infusion of UTTR1147A 90 micrograms/kilogram body weight (μg/kg) on Day 1. A second IV dose of UTTR1147A 90 μg/kg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
Study: NCT05454059

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal Examination
Description: All diagnostic procedures were performed with examination instruments (periodontal probe, dental mirror, x-ray device, etc.). Periodontal clinical index measurements (PI, GI, BOP, PPD, CAL) recorded from all teeth. Routine panoramic radiographs were taken from all patients to determine alveolar bone resorption. Vertical/horizontal bone losses on the radiographs were evaluated and used in the diagnosis of periodontitis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodontal Examination
Description: All diagnostic procedures were performed with examination instruments (periodontal probe, dental mirror, x-ray device, etc.). Periodontal clinical index measurements (PI, GI, BOP, PPD, CAL) recorded from all teeth. Routine panoramic radiographs were taken from all patients to determine alveolar bone resorption. Vertical/horizontal bone losses on the radiographs were evaluated and used in the diagnosis of periodontitis.
Study: NCT03334279

Intervention type: OTHER
Intervention: Cigarette smokers
Description: frequent cigarette smoking for not less than 5 years

Intervention type: OTHER
Intervention: Simultaneous cigarette and cannabis smokers
Description: frequent cigarette and cannabis smoking for not less than 5 years
Study: NCT00267605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FHPADHD
Description: Evidence-based psychological and behavioural distance intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ADHD Standard Care
Study: NCT03114436

Intervention type: OTHER
Intervention: Observational Data Collection
Description: All aspects of deceased donor care in the ICU.
Study: NCT03897946

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Birth dose hepatitis B vaccine
Description: Groups A and C will receive a birth dose of hepatitis B vaccine within 24 hours of life.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Birth dose hepatitis B vaccine
Description: Groups A and C will receive a birth dose of hepatitis B vaccine within 24 hours of life.
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam
Study: NCT01812356

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryomaze procedure using Nitrous oxide
Description: Cryomaze procedure using Nitrous oxide

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryomaze procedure using Argon
Description: Cryomaze procedure using Argon
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam
Study: NCT00541099

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Avastin 10.0 mg/kg on days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Dexamethasone 4 mg evening before, morning of and evening of each dose of docetaxel.Docetaxel 35 mg/m2 on day 1, 8, 15
Study: NCT03244319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Patients who are randomly assigned to edoxaban group will be received 60mg qd or 30mg qd (creatinine clearance 30-49ml/min, body weight \<60kg or concomitant use of certain P-glycoprotein inhibitors).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: All patients who are assigned to VKA group, bridging with warfarin and UFH is mandatory until INR reach therapeutic target range (INR 2-3). Warfarin dose will be adjusted for maintain therapeutic range (INR 2-3) during follow up period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: parenteral anti-coagulant (UFH)
Description: parenteral anti-coagulant (UFH)
Study: NCT04386616

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UTTR1147A-matched Placebo
Description: Participants received up to 2 intravenous infusions of UTTR1147A-matched placebo.
Study: NCT00015873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study: NCT05454059

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal Examination
Description: All diagnostic procedures were performed with examination instruments (periodontal probe, dental mirror, x-ray device, etc.). Periodontal clinical index measurements (PI, GI, BOP, PPD, CAL) recorded from all teeth. Routine panoramic radiographs were taken from all patients to determine alveolar bone resorption. Vertical/horizontal bone losses on the radiographs were evaluated and used in the diagnosis of periodontitis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodontal Examination
Description: All diagnostic procedures were performed with examination instruments (periodontal probe, dental mirror, x-ray device, etc.). Periodontal clinical index measurements (PI, GI, BOP, PPD, CAL) recorded from all teeth. Routine panoramic radiographs were taken from all patients to determine alveolar bone resorption. Vertical/horizontal bone losses on the radiographs were evaluated and used in the diagnosis of periodontitis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal Examination
Description: All diagnostic procedures were performed with examination instruments (periodontal probe, dental mirror, x-ray device, etc.). Periodontal clinical index measurements (PI, GI, BOP, PPD, CAL) recorded from all teeth. Routine panoramic radiographs were taken from all patients to determine alveolar bone resorption. Vertical/horizontal bone losses on the radiographs were evaluated and used in the diagnosis of periodontitis.
Study: NCT03184610

Intervention type: DEVICE
Intervention: OCT-scanning
Description: All participants will be scanned with a OCT-device

Intervention type: DEVICE
Intervention: OCT-scanning
Description: All participants will be scanned with a OCT-device